

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATI		
10/630,203	07/29/2003	Thomas Thisted	10062.210-US	1994	
25908	7590 03/24/2006		EXAMINER		
NOVOZYM 500 FIFTH A	ES NORTH AMERI	CHOWDHURY, IQBAL HOSSAIN			
SUITE 1600	VENUE		ART UNIT	PAPER NUMBER	
NEW YORK	NY 10110	1652			

DATE MAILED: 03/24/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

			Application	No.	Applicant(s)				
			10/630,203 THISTED ET		THISTED ET AL.				
Office Action Summary			Examiner		Art Unit				
			Iqbal Chow		1652				
Period fo	The MAILING DATE of this commun or Reply	nication appe	ears on the d	cover sheet with the c	orrespondence ad	ldress			
WHIC - Externafter - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR THE NEW PERIOD FOR THE NEW PROPERTION OF THE NEW PROPERTION OF THE NEW PROPERTION OF THE NEW PERIOD FOR THE NEW PERIOD FOR THE NEW PERIOD FOR THE NEW PERIOD P	MAILING DA s of 37 CFR 1.13 munication. tatutory period wi y will, by statute,	TE OF THIS 6(a). In no even ill apply and will cause the applic	S COMMUNICATION t, however, may a reply be time expire SIX (6) MONTHS from ation to become ABANDONE	I. tely filed the mailing date of this coorsists U.S.C. § 133).				
Status									
1)	Responsive to communication(s) file	ed on							
•	This action is FINAL . 2b)⊠ This action is non-final.								
,	Since this application is in condition	•—			secution as to the	e merits is			
-,_	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims								
4)⊠	Claim(s) 1-40 is/are pending in the	application.							
, —	4a) Of the above claim(s) is/are withdrawn from consideration.								
	5) Claim(s) is/are allowed.								
•	6) Claim(s) is/are rejected.								
	Claim(s) is/are objected to.								
• • •	8) Claim(s) 1-40 are subject to restriction and/or election requirement.								
Applicati	on Papers								
	The specification is objected to by the	ne Examiner							
,	· · · · · · · · · · · · · · · · · · ·			objected to by the I	Examiner.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
						FR 1.121(d).			
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority (under 35 U.S.C. § 119								
/—	Acknowledgment is made of a claim ☐ All b) ☐ Some * c) ☐ None of:	for foreign	priority unde	er 35 U.S.C. § 119(a)	-(d) or (f).				
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority	documents	have been	received in Applicati	on No				
	3. Copies of the certified copies	-	•		ed in this National	Stage			
	application from the Internation		•						
* (See the attached detailed Office action	on for a list o	of the certific	ed copies not receive	d.				
Attachmen	t(s)								
	e of References Cited (PTO-892)			1) Interview Summary					
	e of Draftsperson's Patent Drawing Review (ı	Paper No(s)/Mail Da		O-152)			
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application (PTO-152) 6) Other:									

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 21-32, drawn to a mutant or variant of an alpha-amylase and a

composition, classified in class 435, subclass 200.

II. Claims 33-37, drawn to a DNA construct comprising a DNA sequence encoding

an alpha-amylase variant, expression vector and host cell, classified in class 435,

subclass 252.3.

The inventions are distinct, each from the other because of the following reasons:

2. The DNA of Group II and the proteins of Group I, are each comprise a chemically

unrelated structure capable of separate manufacture, use and effect. The DNA Group II

comprises a nucleic acid sequence and the proteins of Group I comprises unrelated amino acid

sequences with different structure and functions. The DNA has other utility besides encoding the

proteins such hybridization or probe and the proteins can be made by another method such as

isolation from natural sources or chemical synthesis.

This application contains claims directed to the following patentably distinct species: a

variant of an alpha amylase comprising an alteration at positions: 49, 60, 104, 132, 161, 170,

176, 179, 180, 181, 183, 200, 203, 204, 207, 212, 237, 239, 250,280, 298, 318, 374, 385, 393,

402, 406, 427, 430, 440, 444, 447, 482 of SEQ ID NO: 8. The species are independent or

distinct because each of the variants having distinct structure and distinct function.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for

prosecution on the merits to which the claims shall be restricted if no generic claim is finally

held to be allowable.

Applicant is required, in reply to this action, to elect a single species to which the claims

shall be restricted if no generic claim is finally held to be allowable. The reply must also identify

the claims readable on the elected species, including any claims subsequently added. An

argument that a claim is allowable or that all claims are generic is considered non-responsive

unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of

claims to additional species which are written in dependent form or otherwise include all the

limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after

the election, applicant must indicate which are readable upon the elected species. MPEP §

809.02(a).

Because these inventions are distinct for the reasons given above and have acquired a

separate status in the art as shown by their different classification, restriction for examination

purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37CFR 1.48b if one or more of the currently

named inventors are no longer an inventor of at least one claim remaining in the application. Any

amendment of inventorship must be accompanied by a petition under CFR 1.48 (b) and by the

fee required under 37 CFR 1.17 (i).

Art Unit: 1652

Applicant is advised the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Iqbal H. Chowdhury whose telephone number is 571-272-8137. The examiner can normally be reached on 9:00-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 703-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,

Iqbal Chowdhury, PhD, Patent Examiner Art Unit 1652 (Recombinant Enzymes) US Patent and Trademark Office Rm. Remsen 2B69, Mail Box. 2C70 Ph. (571)-272-8137, Fax. (571)-273-8137 IC

Klausa Kurt